Mammalian target of rapamycin (mtor) inhibition: Potential for antiseizure, antiepileptogenic, and epileptostatic therapy

Current Neurology and Neuroscience Reports

Volumn 12, Issue 4, 2012, Pages 410-418

  Ryther, Robin C C ^a   Wong, Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptogenic; Antiseizure; Epilepsy; Epileptogenesis; Epileptostatic; Everolimus; Mice; mTOR; Rapamycin; Rat; Seizure; Status epilepticus; Therapy; Traumatic brain injury; Tuberous sclerosis complex

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME MECHANISM; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; GENETIC ANALYSIS; HUMAN; INFANTILE SPASM; LATENT PERIOD; MOLECULAR DYNAMICS; NONHUMAN; SEIZURE; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TUBEROUS SCLEROSIS;

EID: 84865630995     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0276-5     Document Type: Article

References (62)

1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345-56.
2. McDaniel SS, Wong M. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett. 2011;497:231-9.
3. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia. 2010;51:27-36.
4. Cho C.H. Frontier of epilepsy research-mTOR signaling pathway. Exp Mol Med. 2011;43:231-74.
5. Weber JD, Gutmann DH. Deconvoluting mTOR biology. Cell Cycle. 2012;11:236-48.
6. Freeman JM, Kossoff EH. Ketosis and the ketogenic diet 2010: advances in treating epilepsy and other disorders. Adv Pediatr. 2010;57:315-29.
7. McDaniel SS, Rensing NR, Thio LL, Yamada KA, Wong M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011;52:e7-e11.
8. Orlova KA, Parker WE, Heuer GG, Tsai V, Yoon J, Baybis M, Fenning RS, Strauss K, Crino PB. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest. 2010;120:1591-602.
9. Crino PB. Molecular pathogenesis of tuber formation in tuberous sclerosis complex. J Child Neurol. 2004;19:716-25. (Pubitemid 39530082)
10. Krueger DA, Care MM, Holland K, Agricola K, et al. Everolimus for subependymal giant-cell astrocytomas in Tuberous Sclerosis. N Engl J Med. 2010;363:1801
11. Baybis M, Yu J, Lee A, Golden JA, Weiner H, McKhann G, Aronica E, Crino PB. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol. 2004;56:478-87. (Pubitemid 39319337)
12. Schick V, Majores M, Engels G, Hartmann W, Elger CE, Schramm J, Schoch S, Becker AJ. Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells. Brain Pathol. 2007;17:165-73. (Pubitemid 46466136)
13. Becker AJ, Urbach H, Scheffler BJ, Baden T, Normann S, Lahl R, Pennek HW, Tuxhorn I, Elger CE, Schramm J, Wiestler OD, Blumcke I. Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to Tuberous Sclerosis. Ann Neurol. 2002;52:29-37. (Pubitemid 34693740)
14. Schonberger A, Niehusmann P, Urbach H, Majores M, Grote A, Holthausen H, Blumcke I, Deckert M, Becker AJ. Increased frequency of distinct TSC2 alleleic variants in focal cortical dysplasias with balloon cells and mineralization. Neuropathology. 2009;29:559-65.
15. Gumbinger C, Rohsbach CB, Schulze-Bonhage A, Korinthenberg R, Zentner J, Haffner M, Fauser S. Focal cortical dysplasia: a genotype-phenotype analysis of polymorphisms and mutations in the TSC genes. Epilepsia. 2009;50:1396-408.
16. GrajkowskiW, Kotulska K,Matyja E, Larysz-Brysz M,Mandera M, Roszkowski M, Domanska-Pakilela D, Lewik-Kowalik J, Jozwiak S. Expression of tuberin and hamartin in tuberous sclerosis complexassociated and sporadic cortical dysplasia of Taylor's balloon cell type. Folia Neuropathol. 2008;46:43-8. (Pubitemid 351559927)
17. Lugnier C, Majores M, Fassunke J, Pernhorst K, Niehusmann P, Simon M, Nellist M, Schoch S, Becker A. Hamartin variants that are frequent in focal dysplasias and cortical tubers have reduced tuberin binding and aberrant subcellular distribution in vitro. J Neuropathol Exp Neurol. 2009;68:1136-46.
18. Ljungberg MC, Bhattacharjee MB, Lu Y, Armstrong DL, Yoshor D, Swann JW, Sheldon M, D'Arcangelo G. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol. 2006;60:420-9. (Pubitemid 44684978)
19. Miyata H, Chiang ACY, Vinters HV. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann Neurol. 2004;56:510-9. (Pubitemid 39319341)
20. Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada KA, Gutmann DH. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol. 2002;52:285-96. (Pubitemid 35001494)
21. Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007;27:5546-58. (Pubitemid 350021088)
22. Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, Anderl S, Malinowska IA, Di Nardo A, Bronson RT, Chan JA, Vinters HV, Kernie SG, Jensen FE, Sahin M, Kwiatkowski DJ. Regulable neural progenitor-specific TSC1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. PNAS. 2011;108:1070-9.
23. Carson RP, Van Nielen DL, Winzenburger PA, Ess KC. Neuronal and glia abnormalities in TSC1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis. 2012;45:369-80.
24. Fu C, Cawthon B, ClinkscalesW, Bruce A,Winzenburger P, Ess KC. GABAergic interneuron development and function is modulated by the Tsc1 gene. Cereb Cortex 2011 Oct 20 Epub ahead of print
25. Way SW, McKenna 3rd J, Mietzsch U, Reith RM, Wu HC, Gambello MJ. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet. 2009;18:1252-65.
26. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a TSC2+/? mouse model of tuberous sclerosis. Nat Med. 2008;14:843-8.
27. Zeng L, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. TSC2 gene inactivation causes a more severe epilepsy phenotype than TSC1 inactivation in a mouse model of Tuberous Sclerosis Complex. Hum Mol Genet. 2011;20:445-54.
28. Zeng L, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of Tuberous Sclerosis Complex. Ann Neurol. 2008;63:444-53. (Pubitemid 351614710)
29. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski. Response of a neuronal model of Tuberous Sclerosis to mammalian target of Rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28:5422-32.
30. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, et al. PTEN mutation spectrum and genotype - phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8:1461-72. (Pubitemid 29374079)
31. Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J, TsaoMS, Shannon P, Bolon B, Ivy GO, MakTW. Deletion of Pten in mouse brain causes seizures, ataxia, and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet. 2001;29:396-403. (Pubitemid 34326689)
32. Kwon CH, Zhu X, Zhang J, Knoop LL, Tharp R, Smeyne RJ, Eberhart CG, Burger PC, Baker SJ. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet. 2001;29:404-11. (Pubitemid 34326690)
33. Kwon C, Zhu X, Zhang J, Baker SJ. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci USA. 2003;100:12923-8. (Pubitemid 37340001)
34. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G. Rapamycin suppresses seizures and neuronal hypertrophy in a mousemodel of cortical dysplasia. Dis Model Mech. 2009;2:389-98.
35. Sunnen CN, Brewster AL, Lugo JN, Vanegas F, Turclos E, Mukhi S, Parghi D, D'Arcangelo G, Anderson AE. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia. 2011;52:206575.
36. Zhou J, Blundell J, Ogawa S, Kwon C, Zhang W, Sinton C, Powell CM, Parada LF. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci. 2009;29:1773-83.
37. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci. 2009;29:696472.
38. Buckmaster PS, Ingram EA, Wen X. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci. 2009;29:8259-69.
39. Huang X, Zhang H, Yang J, Wu J, McMahon J, Lin Y, Cao Z, Gruenthal M, Huang Y. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis. 2010;40:193-9.
40. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci. 2011;31:233747.
41. Sliwa A, Plucinska G, Bednarczyk J, Lukasiuk K. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett. 2012; Epub ahead of print
42. Wong M. Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither? Epilepsy Curr. 2011;11:66-8.
43. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 2001;42:515-24. (Pubitemid 32322197)
44. Chen S, Atkins CM, Liu CL, Alonso OF, Dietrich WD, Hu BR. Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury. J Cereb Blood Flow Metab. 2007;27:939-49. (Pubitemid 46659022)
45. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis. 2007;26:86-93. (Pubitemid 46436489)
46. Guo D, Zeng LH, Brody DL, Wong M. mTOR inhibition has potential antiepileptogenic effects in a controlled cortical impact model of traumatic brain injury. Epilepsy Curr. 2011;11(Suppl 1): Abstract #1.014
47. Park J, Zhang J, Qiu J, Zhu X, Degterev A, Lo EH, Whalen MJ. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact. J Cereb Blood Flow Metab. 2012;32:330-40.
48. Berdichevsky Y, Saponjian Y, Mail M, Staley KJ. Organotypic culture model of post-traumatic epileptogenesis used as a mediumthroughput screen of antiepileptic drugs. Epilepsy Curr. 2012;12 (Suppl 1): Abstract #3.026
49. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulo AS. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis. 2011;43:322-8.
50. Chachua T, Yum MS, Veliskova J, Velisek L. Validation of the rat model of cryptogenic infantile spasms. Epilepsia. 2011;52:1666-77.
51. Talos DM, Sun H, Jackson M, Joseph A, Fitzgerald E, Jensen F. Rapamycin attenuates the increases in seizure susceptibility and neuronal excitability following neonatal seizures in rat. Epilepsy Curr. 2011;11(Suppl 1):Abstract A.08
52. Sankar R, Auvin S, Kwon YS, Pineda E, Shin D, Mazarati A. Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia. 2010;51(Suppl3):39-42.
53. Muncy J, Butler IJ, Koenig M. Rapaymycin reduces seizure frequency in Tuberous Sclerosis Complex. J Child Neurol. 2009;24:477.
54. Wilfong A, Krueger DA, Holland-Bouley K, Anderson AE, Agricola K, Schultz RJ, Tudor C, Mayws M, Lopez CM, Franz DN. Everolimus improves seizure control in tuberous sclerosis complex. American Epilepsy Society Meeting Abstracts 2011; Late-breaking Abstract #3.329
55. Daoud D, Scheld HH, Speckmann EJ, Gorji A. Rapamycin: brain excitability studied in vitro. Epilepsia. 2007;48:834-6. (Pubitemid 46587621)
56. Ruegg S, Baybis M, Juul H, Dichter M, Crino PB. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res. 2007;77:85-92. (Pubitemid 350137689)
57. Galanopoulou A, Crino P, Wong M, Buckmaster P, Raffo E. Rapamycin: from tuberous sclerosis and beyond. Epilepsia. 2009;50 Suppl 11:309.
58. Anderl S, Freeland M, Kwiatkowski DJ, Goto J. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet. 2011;20:4597-604.
59. Guardia O, del Rial MC, Casadei D. Pregnancy under sirolimusbased immunosuppression. Transplantation. 2006;81:636.
60. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698-702. (Pubitemid 46035654)
61. Chu SH, Liu KL, Chiang YJ, Wang HH, Lai PC. Sirolimus used during pregnancy in a living related renal transplant recipient: a case report. Transplant Proc. 2008;40:2446-8.
62. Jozwiak S, Kotulsaka K, Domanska-Pakilea D, Lojszczyk B, Syczewska M, Chmielewski D, Dunin-Wasocwicz D, Kmiec T, Szymkiewicz-Dangel J, Kornacka M, Kawalec W, Kuczynski D, Borkowska J, Tomaszek K, Jurkiewicz E, Respondek-Liberska M. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011;15:424-31.